A number of commercial spin off companies have emerged from the research of investigators comprising the Applied Neurotherapeutics Research Group
|
|
||
|
A number of commercial spin off companies have emerged from the research of investigators comprising the Applied Neurotherapeutics Research Group |
||
|
|
|
Neuropharmacology
Berand is a new pharma initiative delivering preclinical profiling of novel chemical entities. We focus on the evaluation of promising drugs directed against diseases of the mind including neurodegenerative psychotic conditions, such as Alzheimer's disease and schizophrenia. New chemical entities are evaluated in our behavioual repertoire that combines biochemical and cellular read-outs. Berand aims to generate its own in-house IP through the identification of lead chemicals derived from cheminformatic database searching.
|
|
Analytical Drug and Data (ADD) Ltd. was founded in Dublin, Ireland in 2001. As with most new hi-tech companies we still retain close connections with academic institutions, in our case University College Dublin. We cooperate with scientists all over the world with emphasis on continuing scientific support. Our mission is to understand illness of mind and brain as a disorder of the nerve network using microdialysis in intact conscious brain. With the aid of new drugs/ligands we are investigating how a dysregultion in the nerve network leads to illnesses such as schizophrenia, depression, epilepsy and Parkinson’s disease. We are located in the grounds of University College Dublin and sincerely hope that you will pay us a visit when you are in Dublin.
|
|
Genable
Limited (Campus Company - Trinity College Dublin) Genable offers a novel
therapeutic approach to the treatment of disease through suppression
and/or replacement (SuRe) of genes involved in the disease process.
The technologies utilise inherent features of the genome to circumvent the
mutational diversity present in many genetic disorders. Such an approach
has great potential in the treatment of a wide range of genetic disorders.
Genable's technologies to do this have arisen from the research of Dr.
Jane Farrar, Prof. Peter Humphries and Dr Paul Kenna. They have
generated a suite of molecular tools that are now being adapted to develop
treatments for inherited blindness and brittle bone disease. The
technologies are being commercialised under the direction of Dr Gearoid Tuohy, CEO. Notably, the SuRe technologies while focused towards two
initial lead products, are platform in nature, and may in principle be applied in the
development of therapies for a myriad of diseases. Dr. Gearoid Tuohy, CEO Ph 00 353 1 608 3390
Dr. Jane Farrar Ph 00 353 1 608 3694 |
|
ANRG | Conway Home | UCD Home
|
